• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

洗涤剂介导的从酿酒酵母匀浆中释放乙型肝炎病毒样颗粒的研究:确定下一代脂蛋白疫苗生产工艺设计的框架。

Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes.

作者信息

Kee Gaik Sui, Pujar Narahari S, Titchener-Hooker Nigel J

机构信息

The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK.

出版信息

Biotechnol Prog. 2008 May-Jun;24(3):623-31. doi: 10.1021/bp070472i. Epub 2008 Apr 23.

DOI:10.1021/bp070472i
PMID:18429641
Abstract

Virus-like particles (VLPs) are expressed intracellularly in Saccharomyces cerevisiae and the recovery process involves the use of a detergent, which facilitates the release of VLP from host cell components. The detergent-mediated liberation of VLPs is a critical step in primary recovery and is responsible for setting the backdrop for subsequent purification in terms of product yield and characteristics of the process stream. In this paper the use of Triton X-100 detergent for the recovery of lipid envelope VLPs, using the hepatitis B surface antigen (HBsAg) as the VLP model, was investigated. To develop a framework that can be adopted in process design for future generation VLP vaccine candidates, the impact of Triton X-100 was characterized via different response factors: (i) recovery and activity of the HBsAg; (ii) level of protein and lipid contamination from the host cell; and (iii) indirect impact on the performance of an ultrafiltration step following primary recovery. Our studies identified that an increase in detergent concentration favors recovery of HBsAg only to a specific threshold, 0.5% v/v Triton X-100. Further increase in detergent results in delipidation of HBsAg leading to loss in antigenic activity. The level of contamination due to host protein and lipid co-liberation is in proportion with the amount of detergent employed. Greater membrane resistance during ultrafiltration was observed for samples generated using higher concentrations of detergent due to the increase in membrane fouling by the contaminants. Based on this study, Triton X-100 concentrations in the range of 0.2-0.5% v/v appears to be most suitable for recovery of native HBsAg. Choosing between 0.2-0.5% v/v would involve identifying a suitable tradeoff between desired product yield and the level of contamination that can be tolerated by downstream operations.

摘要

病毒样颗粒(VLPs)在酿酒酵母细胞内表达,回收过程需要使用去污剂,以促进VLPs从宿主细胞成分中释放出来。去污剂介导的VLPs释放是初次回收的关键步骤,在产品产量和工艺流特性方面为后续纯化奠定了基础。本文以乙型肝炎表面抗原(HBsAg)作为VLPs模型,研究了使用Triton X-100去污剂回收脂质包膜VLPs的情况。为了建立一个可用于下一代VLP候选疫苗工艺设计的框架,通过不同的响应因素对Triton X-100的影响进行了表征:(i)HBsAg的回收率和活性;(ii)宿主细胞中蛋白质和脂质的污染水平;(iii)对初次回收后超滤步骤性能的间接影响。我们的研究发现,去污剂浓度的增加仅在特定阈值(0.5% v/v Triton X-100)之前有利于HBsAg的回收。去污剂浓度进一步增加会导致HBsAg的脱脂,从而导致抗原活性丧失。宿主蛋白和脂质共同释放引起的污染水平与所用去污剂的量成正比。由于污染物导致的膜污染增加,使用较高浓度去污剂产生的样品在超滤过程中观察到更大的膜阻力。基于这项研究,0.2 - 0.5% v/v范围内的Triton X-100浓度似乎最适合回收天然HBsAg。在0.2 - 0.5% v/v之间进行选择需要在期望的产品产量和下游操作可容忍的污染水平之间找到合适的平衡点。

相似文献

1
Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes.洗涤剂介导的从酿酒酵母匀浆中释放乙型肝炎病毒样颗粒的研究:确定下一代脂蛋白疫苗生产工艺设计的框架。
Biotechnol Prog. 2008 May-Jun;24(3):623-31. doi: 10.1021/bp070472i. Epub 2008 Apr 23.
2
Exploiting the intracellular compartmentalization characteristics of the S. cerevisiae host cell for enhancing primary purification of lipid-envelope virus-like particles.利用 S. cerevisiae 宿主细胞的细胞内区室化特征,增强脂包膜病毒样颗粒的初步纯化。
Biotechnol Prog. 2010 Jan-Feb;26(1):26-33. doi: 10.1002/btpr.307.
3
Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties.从重组毕赤酵母中纯化乙型肝炎表面抗原病毒样颗粒及其体内免疫原性分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 1;940:104-11. doi: 10.1016/j.jchromb.2013.09.030. Epub 2013 Sep 27.
4
Selective flocculation and precipitation for the improvement of virus-like particle recovery from yeast homogenate.用于提高从酵母匀浆中回收病毒样颗粒的选择性絮凝和沉淀法。
Biotechnol Prog. 2000 Jul-Aug;16(4):661-7. doi: 10.1021/bp0000407.
5
Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment.实时监测 HBsAg 病毒样颗粒 (VLPs) 在热和氧化还原处理过程中抗原性的发展。
Biochem Biophys Res Commun. 2011 May 13;408(3):447-53. doi: 10.1016/j.bbrc.2011.04.048. Epub 2011 Apr 19.
6
Advances in primary recovery: centrifugation and membrane technology.一次采油技术进展:离心法与膜技术
Biotechnol Prog. 2008 May-Jun;24(3):488-95. doi: 10.1021/bp070414x. Epub 2008 Apr 15.
7
Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing.评估下游加工过程中乙型肝炎表面抗原向病毒样颗粒的稳定性和组装情况。
Vaccine. 2015 Jul 17;33(31):3739-45. doi: 10.1016/j.vaccine.2015.05.066. Epub 2015 Jun 12.
8
Factors important in the extraction, stability and in vitro assembly of the hepatitis B surface antigen derived from recombinant plant systems.来自重组植物系统的乙型肝炎表面抗原在提取、稳定性及体外组装过程中的重要因素。
Biotechnol Prog. 2002 May-Jun;18(3):538-50. doi: 10.1021/bp010169w.
9
An automated microscale chromatographic purification of virus-like particles as a strategy for process development.作为一种工艺开发策略的病毒样颗粒的自动化微量色谱纯化
Biotechnol Appl Biochem. 2007 Jun;47(Pt 2):131-9. doi: 10.1042/BA20060240.
10
Factors determining detergent resistance of erythrocyte membranes.决定红细胞膜抗去污剂能力的因素。
Biophys Chem. 2008 Jun;135(1-3):14-8. doi: 10.1016/j.bpc.2008.02.015. Epub 2008 Mar 6.

引用本文的文献

1
HBV Vaccines: Advances and Development.乙肝疫苗:进展与发展
Vaccines (Basel). 2023 Dec 18;11(12):1862. doi: 10.3390/vaccines11121862.
2
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.探索基于 FeLV-Gag 的 VLPs 作为新型疫苗平台:生产与免疫原性分析。
Int J Mol Sci. 2023 May 19;24(10):9025. doi: 10.3390/ijms24109025.
3
Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery.基于酵母的病毒样颗粒作为疫苗开发与递送的新兴平台
Vaccines (Basel). 2023 Feb 18;11(2):479. doi: 10.3390/vaccines11020479.
4
Generating Recombinant Antibodies to Membrane Proteins through Phage Display.通过噬菌体展示技术生成针对膜蛋白的重组抗体。
Antibodies (Basel). 2016 May 2;5(2):11. doi: 10.3390/antib5020011.
5
Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.重组人博卡病毒 1.2 型 VP2 基因病毒样颗粒在小鼠中的免疫原性。
Immunology. 2014 May;142(1):58-66. doi: 10.1111/imm.12202.